NASDAQ:CRBP Corbus Pharmaceuticals Q3 2025 Earnings Report $12.00 -0.15 (-1.20%) As of 10:46 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Corbus Pharmaceuticals EPS ResultsActual EPS-$1.90Consensus EPS -$1.80Beat/MissMissed by -$0.10One Year Ago EPSN/ACorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.11 millionBeat/MissN/AYoY Revenue GrowthN/ACorbus Pharmaceuticals Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Corbus Pharmaceuticals Earnings HeadlinesCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors2 hours ago | globenewswire.comCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 13 at 7:00 AM | globenewswire.comThe US sanctioned itself out of world reserve status…Russia and Iran are both bypassing the US petrodollar - settling oil trades in alternative currencies while central banks buy gold at the fastest pace on record, four years running. Analyst Garrett Goggin, CFA, CMT says his readers are already sitting on gains of 1,200% over the last two years. He believes the gold bull market has more room to run - and four undervalued miners may offer more upside than bullion at today's prices.May 14 at 1:00 AM | Golden Portfolio (Ad)Corbus Pharmaceuticals Reports FDA Alignment and Positive Developments for CRB-701 and CRB-913 ProgramsMay 12 at 8:30 AM | quiverquant.comQCorbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate UpdateMay 12 at 8:00 AM | globenewswire.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock Passes Above Fifty Day Moving Average - Should You Sell?May 12 at 3:50 AM | americanbankingnews.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders. Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation. The company has also received orphan drug and Fast Track designations for lenabasum in systemic sclerosis and dermatomyositis, underscoring regulatory recognition of its potential to address conditions with limited treatment options. Corbus continues to explore additional indications for its pipeline operations, seeking partnerships and collaborations to support late-stage development and eventual commercialization. Founded in 2006 and headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals primarily serves patients in North America and Europe through its clinical trial network. Under the leadership of President and Chief Executive Officer Kenneth T. Leonard and Chief Financial Officer Robert J. Conway, the company remains focused on advancing innovative therapies for complex inflammatory diseases and positioning itself as a leader in resolution pharmacology.View Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunD-Wave Earnings Looked Weak, But Investors May Be Missing ThisChime Finally Turns Profitable—But Risks RemainHow Berkshire’s New York Times Bet Looks TodayPlug Power Flips The Switch On ProfitabilityHims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery? Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
